Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction.
Fiche publication
Date publication
novembre 2018
Journal
British journal of clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier
Tous les auteurs :
Narjoux G, Clarenne J, Azzouz B, Zeller PS, Slimano F, Bouché O
Lien Pubmed
Résumé
Polypharmacy of elderly oncology patients and fragmented medication management are well-known risk factors for drug-drug interactions (DDIs). These interactions can occur among antineoplastic, ongoing chronic treatment(s) and chemotherapy-associated treatments, like antiemetics. Clinically relevant interactions based on enzyme- or transporter-inhibition phenomena of active drugs can increase the frequency of their DDIs. We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan-based regimen manifested by nightmares and visual hallucinations. We discuss this DDI's hypothetical pharmacological mechanisms and management.
Mots clés
OCT1, UGT2B7, aprepitant, drug-drug interaction, irinotecan, opium powder
Référence
Br J Clin Pharmacol. 2018 Nov 26;: